Last updated: 2026-09-09 19:55:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Castle Biosciences, Inc. (CSTL) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $32.45, with a market capitalization of $1.01B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.72 to $44.28. This page covers its latest market performance, valuation, price trends and company information.
$1.01B | |
$33.04 | |
$107.69 | |
$2.26 | |
$32.76 | |
112.73K | |
394.39K | |
-- | |
$44.28 | |
$17.72 | |
-- | |
-- |
Castle Biosciences, Inc. (CSTL) is currently trading at $32.45 as of 2026-09-09 19:53:00, down 0.94% ($0.31) from the previous close of $32.76
During today's regular trading session, CSTL has traded between $2.26 and $107.69, with a trading volume of 112.73K shares. The current price is near the lower end of today's range.
Over the past seven days, Castle Biosciences, Inc. (CSTL) moved from $33.50 to $32.45, representing a decline of 3.13% ($1.05).
The stock traded between $31.95 and $34.73 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 271.40 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 55.5%
CSTL is currently trading at $32.45, placing it 55.5% of the way from its 52-week low of $17.72 to its 52-week high of $44.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 1002 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Castle Biosciences, Inc. (CSTL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.